Change search
Link to record
Permanent link

Direct link
Publications (3 of 3) Show all publications
Bergvall, N., Cheah, Y. W., Bernlind, C., Bernlind, A., Olsson, L., Creaser, D., . . . Öhrman, O. G. (2024). Upgrading of fast pyrolysis bio-oils to renewable hydrocarbons using slurry- and fixed bed hydroprocessing. Fuel processing technology, 253, Article ID 108009.
Open this publication in new window or tab >>Upgrading of fast pyrolysis bio-oils to renewable hydrocarbons using slurry- and fixed bed hydroprocessing
Show others...
2024 (English)In: Fuel processing technology, ISSN 0378-3820, E-ISSN 1873-7188, Vol. 253, article id 108009Article in journal (Refereed) Published
Abstract [en]

Liquefaction of lignocellulosic biomass through fast pyrolysis, to yield fast pyrolysis bio-oil (FPBO), is a technique that has been extensively researched in the quest for finding alternatives to fossil feedstocks to produce fuels, chemicals, etc. Properties such as high oxygen content, acidity, and poor storage stability greatly limit the direct use of this bio-oil. Furthermore, high coking tendencies make upgrading of the FPBO by hydrodeoxygenation in fixed-bed bed hydrotreaters challenging due to plugging and catalyst deactivation. This study investigates a novel two-step hydroprocessing concept; a continuous slurry-based process using a dispersed NiMo-catalyst, followed by a fixed bed process using a supported NiMo-catalyst. The oil product from the slurry-process, having a reduced oxygen content (15 wt%) compared to the FPBO and a comparatively low coking tendency (TGA residue of 1.4 wt%), was successfully processed in the downstream fixed bed process for 58 h without any noticeable decrease in catalyst activity, or increase in pressure drop. The overall process resulted in a 29 wt% yield of deoxygenated oil product (0.5 wt% oxygen) from FPBO with an overall carbon recovery of 68%.

Place, publisher, year, edition, pages
Elsevier B.V., 2024
Keywords
Biofuel, Deoxygenation, Hydroprocessing, Pyrolysis, Renewable, Slurry, Biofuels, Catalyst deactivation, Fuel storage, Oxygen, Deoxygenations, Fast pyrolysis bio-oil, Fixed bed, Fixed-bed process, Lignocellulosic biomass, Ni-Mo catalyst, Oil product, Oxygen content, Catalyst activity
National Category
Chemical Engineering
Identifiers
urn:nbn:se:ri:diva-71914 (URN)10.1016/j.fuproc.2023.108009 (DOI)2-s2.0-85179611112 (Scopus ID)
Funder
Swedish Energy Agency, 41253-2
Note

 Correspondence Address: N. Bergvall; Research Institutes of Sweden AB, Borås, Box 857, SE-501 15, Sweden; This work was funded by the Swedish Energy Agency, project number 41253-2

Available from: 2024-02-22 Created: 2024-02-22 Last updated: 2024-05-17Bibliographically approved
Hammarström, L. G. J., Harmel, R. K., Granath, M., Ringom, R., Gravenfors, Y., Färnegårdh, K., . . . Ernfors, P. (2016). The Oncolytic Efficacy and in Vivo Pharmacokinetics of [2-(4-Chlorophenyl)quinolin-4-yl](piperidine-2-yl)methanol (Vacquinol-1) Are Governed by Distinct Stereochemical Features. Journal of Medicinal Chemistry, 59(18), 8577-8592
Open this publication in new window or tab >>The Oncolytic Efficacy and in Vivo Pharmacokinetics of [2-(4-Chlorophenyl)quinolin-4-yl](piperidine-2-yl)methanol (Vacquinol-1) Are Governed by Distinct Stereochemical Features
Show others...
2016 (English)In: Journal of Medicinal Chemistry, ISSN 0022-2623, E-ISSN 1520-4804, Vol. 59, no 18, p. 8577-8592Article in journal (Refereed) Published
Abstract [en]

Glioblastoma remains an incurable brain cancer. Drugs developed in the past 20 years have not improved the prognosis for patients, necessitating the development of new treatments. We have previously reported the therapeutic potential of the quinoline methanol Vacquinol-1 (1) that targets glioblastoma cells and induces cell death by catastrophic vacuolization. Compound 1 is a mixture of four stereoisomers due to the two adjacent stereogenic centers in the molecule, complicating further development in the preclinical setting. This work describes the isolation and characterization of the individual isomers of 1 and shows that these display stereospecific pharmacokinetic and pharmacodynamic features. In addition, we present a stereoselective synthesis of the active isomers, providing a basis for further development of this compound series into a novel experimental therapeutic for glioblastoma.

National Category
Analytical Chemistry
Identifiers
urn:nbn:se:ri:diva-13637 (URN)10.1021/acs.jmedchem.6b01009 (DOI)2-s2.0-84988683885 (Scopus ID)
Available from: 2016-10-10 Created: 2016-10-10 Last updated: 2023-06-05Bibliographically approved
Malmquist, J., Bernlind, A. & Lindberg, S. (2013). Imaging agent of a TRPA1 inhibitor (ed.). Journal of labelled compounds & radiopharmaceuticals, 56(9-10), 536-537
Open this publication in new window or tab >>Imaging agent of a TRPA1 inhibitor
2013 (English)In: Journal of labelled compounds & radiopharmaceuticals, ISSN 0362-4803, E-ISSN 1099-1344, Vol. 56, no 9-10, p. 536-537Article in journal (Refereed) Published
Abstract [en]

A method for the preparation of [3'-3H]-4-(2'-chloro-6'- hydroxyphenyl)-2-thioxo-3,4-dihydro-1H-indeno[1,2-d]pyrimidin-5 (2H)-one (1), a TRPA1 inhibitor, was developed for the evaluation of imaging properties of a class of TRPA1 inhibitors. 1 was prepared via tritiation of a protected benzaldehyde followed by a tetrachlorosilane catalyzed multicomponent one-step fusion and was obtained at a specific activity of 0.9 TBq/mmol. A 3H-NMR spectrum on 13.5MBq at 75 μM was recorded.

Keywords
3H, Isotopically labeled synthesis, NMR, TRPA1
National Category
Natural Sciences
Identifiers
urn:nbn:se:ri:diva-6554 (URN)10.1002/jlcr.3030 (DOI)2-s2.0-84894342540 (Scopus ID)23838 (Local ID)23838 (Archive number)23838 (OAI)
Available from: 2016-09-08 Created: 2016-09-08 Last updated: 2023-05-09Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-8849-234x

Search in DiVA

Show all publications